Merck Kgaa MERCK ORD SHS/  DE0006599905  /

London International
2024-05-24  6:35:00 PM Chg. - Volume Bid5:40:08 PM Ask5:40:08 PM Market Capitalization Dividend Y. P/E Ratio
167.70EUR - 147,844
Turnover: 978,885.25
-Bid Size: - -Ask Size: - 17.68 bill.EUR 1.61% 21.08

Business description

Merck is a leading science and technology company in healthcare, life science and performance materials. Around 52,000 employees work to further develop technologies that improve and enhance life – from biopharmaceutical therapies to treat cancer or multiple sclerosis, cutting-edge systems for scientific research and production, to liquid crystals for smartphones and LCD televisions. Founded in 1668, Merck is the world's oldest pharmaceutical and chemical company. The founding family remains the majority owner of the publicly listed corporate group. Merck, Darmstadt, Germany holds the global rights to the Merck name and brand. The only exceptions are the United States and Canada, where the company operates as EMD Serono, MilliporeSigma and EMD Performance Materials.
 

Management board & Supervisory board

CEO
Belén Garijo
Management board
Marcus Kuhnert, Dr. Kai Beckmann, Matthias Heinzel, Peter Guenter
Supervisory board
Dr. Wolfgang Büchele, Sascha Held, Alexander Putz, Anne Lange, Christian Raabe, Daniel Thelen, Dietmar Oeter, Gabriele Eismann, Helene von Roeder, Helga Rübsamen-Schaeff, Jürgen Glaser, Michael Kleinemeier, Peter Emanuel Merck, Renate Koehler, Simon Thelen, Birgit Biermann
 

Company data

Name: Merck KGaA
Address: Frankfurter Str. 250,D-64293 Darmstadt
Phone: +49-6151-72-0
Fax: +49-6151-72-2000
E-mail: service@merckgroup.com
Internet: www.merck.de
Industry: Healthcare
Sector: Pharmaceutical Industry
Sub sector: Pharmaceuticals
End of financial year: 12-31
Free Float: 66.28%
IPO date: 1995-10-20

Investor relations

Name: Constantin Fest
IR phone: +49-6151-72-3321
IR Fax: +49-6151-72-91-3321
IR e-mail: investor.relations@m...oup.com investor.relations@merckgroup.com

Company calendar

CW 10 | 2025-03-06 Annual Report
CW 17 | 2025-04-25 General Shareholder Meeting
CW 20 | 2025-05-15 Interim Report 1st Quarter/3 Months
CW 32 | 2025-08-07 Interim Report 2nd Quarter/6 Months
CW 46 | 2025-11-13 Interim Report 3rd Quarter/9 Months
 

Main Shareholders

Others
 
73.64%
BlackRock, Inc.
 
7.43%
Massachusetts Financial Services Company
 
5.06%
Sun Life Financial Inc.
 
4.91%
FMR LLC
 
3.02%
Amundi S.A.
 
2.99%
DWS Investment GmbH
 
2.95%